Compare Estee Lauder Companies Inc (EL) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Estee Lauder Companies Inc vs Twist Bioscience Corp — how do they compare? Estee Lauder Companies Inc trades at $98.05 (market cap $34.17B), while Twist Bioscience Corp trades at $159.78 (market cap $10.08B). The key difference: Estee Lauder Companies Inc is far larger — about 3.4× Twist Bioscience Corp's market cap, and Estee Lauder Companies Inc pays a 1.48% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Estee Lauder Companies Inc for 122 Days and Twist Bioscience Corp for 27 Days on average.
| EL | TWST | |
|---|---|---|
Market Cap | $34.17B | $10.08B |
Volume | 3,921,497 | 4,229,037 |
Sector | Consumer Staples | Health |
52-Week High | $119.61 | $205.00 |
52-Week Low | $67.23 | $25.45 |
Typical Hold Time | 122 Days | 27 Days |
Enterprise Value | $39.92B | $10.01B |
Dividend Yield | 1.48% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Estée Lauder (EL) trades at $94.32, down 0.14% with neutral technical signals. The company shows mixed fundamentals with a high P/E of 188.64 but strong gross margins of 75.5%. Recent earnings beats and a $0.35 dividend signal management confidence, though 2025 saw a net loss of $1.13B. Analyst consensus is evenly split between Buy and Hold with a $103 price target.
EL faces execution risks amid competitive pressures, but strategic partnerships in AI and leadership changes may support a turnaround. The stock offers potential upside to analyst targets if margin improvements and revenue growth materialize, though high valuation and recent profitability challenges warrant caution.
TWST trades at $152.05, down 2.31% today, with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported Q2 2026 EPS of -$0.56, missing expectations, continuing a trend of losses despite revenue growth to $376.57M in 2025. Recent news highlights a partnership with Lilly TuneLab for AI-driven drug discovery, driving investor optimism.
Outlook remains speculative with high valuation multiples (P/S 21.5, P/B 22.62) and persistent losses, but analyst consensus is bullish (73% buy ratings) with a $145.20 price target. Key risks include cash burn, competitive pressures, and reliance on AI-driven growth catalysts for profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Estee Lauder Companies Inc
Estee Lauder is the world leader in the global prestige beauty market, participating across skincare (56% of fiscal 2022 sales), makeup (26%), fragrance (14%), and haircare (4%) categories, with popular brands such as Estee Lauder, Clinique, MAC, La Mer, Jo Malone, Aveda, Bobbi Brown, Too Faced, Origins, Dr. Jart+, and The Ordinary. The firm operates in 150 countries, with 26% of fiscal 2022 revenue stemming from the Americas, 43% from Europe, the Middle East, and Africa, and 31% from Asia-Pacific. The company sells its products through department stores, travel retail, multi-brand specialty beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
Read more on EL →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
